Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 3 1

Status

Completed 19Recruiting 6Terminated 4Active not recruiting 3Withdrawn 1Unknown 1Not yet recruiting 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 112Other solid neoplasm 8Tumor-Agnostic 6Thoracic 6Lymphoid 6Other hematologic neoplasm 5Gynecologic 5Sarcoma 2Head & Neck 2Genitourinary 2Dermatologic 2CNS 2Myeloid 1Breast 1

Conditions

Adenocarcinoma 4Neoplasms 3Neoplasm Metastasis 1

Interventions

pembrolizumab 26Specimen Handling 17Blood Specimen Collection 17Biopsy 16Magnetic Resonance Spectroscopy 15atezolizumab 11Surveys and Questionnaires 11Bevacizumab 9Radiotherapy 8Radiosurgery 8Nivolumab 8Fluorouracil 8Standard of Care 7Paclitaxel 7Irinotecan 7Gemcitabine 7Cisplatin 7olaparib 6durvalumab 6Palliative Care 6Oxaliplatin 6Leucovorin 6Cyclophosphamide 6Carboplatin 6Capecitabine 6alectinib 5abemaciclib 5Trastuzumab 5Interviews as Topic 5Exercise 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × Leucovorin × Tumor-Agnostic × Clear all
NCT06901531 2026-06-05

LUCERNA

Astellas Pharma Inc

Phase 3 Recruiting
500 enrolled
Tumor-Agnostic

Adenocarcinoma, Neoplasms

NCT03899155 2026-06-03

Pan Tumor Rollover Study

Bristol-Myers Squibb

Phase 2 Recruiting
1,500 enrolled
Tumor-Agnostic

Neoplasms

NCT05365581 2026-05-28

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Astellas Pharma Inc

Phase 1 Recruiting
398 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT05382559 2026-04-14

A Study of ASP3082 in Adults With Advanced Solid Tumors

Astellas Pharma Inc

Phase 1 Recruiting
681 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT04361708 2025-10-01

I-FLOAT

University of Chicago

Phase 1 Recruiting
54 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT07018570 2025-08-26

An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma

National Cancer Center Hospital East

Phase 2 Recruiting
26 enrolled
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡